Cortrophin gel is purified corticotropin (ACTH), an important treatment option for patients struggling with certain chronic autoimmune disorders. It acquired the NDA for cortrophin gel from Merck & Co. in 2016
Expertise in exosomes isolation and characterization will drive innovation in this field
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
Acute therapies continue to report strong growth compared to chronic ones.
Cipla has reported consolidated financial results for the period ended September 30, 2021
The collaboration aims to deliver greater insights to the oncology fraternity, predict patient therapy responses and enable therapy selection resulting in optimal treatment outcomes.
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
This strategic collaboration will enable continued innovation in cancer care
It has exercised intellectual property options from IP Group regarding research results generated by the UK Cystic Fibrosis Gene Therapy Consortium, and from Oxford Biomedica regarding their lentiviral vector technology
Subscribe To Our Newsletter & Stay Updated
